Also trades as: 0R1F.L (LSE) · $vol 1M · 0R1F.IL (IOB) · $vol 1M · BRM.DE (XETRA) · $vol 0M · BMY.SW (SIX) · $vol 0M
BMY NYSE
Bristol-Myers Squibb Company
1W: +4.7%
1M: -1.0%
3M: -2.1%
YTD: +18.9%
1Y: +46.8%
3Y: +25.6%
5Y: +33.1%
$61.55
-0.06 (-0.10%)
After Hours: $61.90 (+0.35, +0.57%)
Weekly Expected Move ±5.2%
$55
$58
$61
$65
$68
Credit Risk of going bust: lower than 72% of companies Debt: 25.5% of company value Bonds: $498.7M held by 336 funds, 76 bp over Treasuries → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.26 (down 98%), Bristol-Myers Squibb Company would be worth roughly what it owes.
Total debt $43.12B against a stock market value of $125.85B.
Distance to default 7.92 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $22.07B (short-term plus half of long-term), stock volatility 28.2%; Altman Z 2.67. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $1.26 (down 98%), Bristol-Myers Squibb Company would be worth roughly what it owes.
Total debt $43.12B against a stock market value of $125.85B.
Distance to default 7.92 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $22.07B (short-term plus half of long-term), stock volatility 28.2%; Altman Z 2.67. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
13 relationships0
As Filer
counterparties named
13
As Counterparty
mentioned by others
2021-05-18
Earliest Filing
2026-02-27
Latest Filing
Mentioned As Counterparty
13 mentionsOther companies that named BMY in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| RNAM Avidity Biosciences, Inc. | partner | Counterparty to collaboration agreements retained by SpinCo | 2026-02-27 | View |
| RNA Atrium Therapeutics, Inc. | partner | Collaboration partner whose agreement was transferred to the spun-off company. | 2026-02-27 | View |
| JANX Janux Therapeutics, Inc. | partner | Exclusive license and collaboration agreement to develop and commercialize a tumor-activated therapeutic. | 2026-01-22 | View |
| BEAM Beam Therapeutics Inc. | target | Completed acquisition of Orbital Therapeutics, Inc. | 2025-12-11 | View |
| PRME Prime Medicine, Inc. | partner | Parent company of Juno Therapeutics; entered into a Research Collaboration and License Agreement and a Securities Purcha | 2024-09-30 | View |
| LIANY LianBio | partner | Licensor party in terminated exclusive license agreement for mavacamten | 2023-10-30 | View |
| BBIO BridgeBio Pharma, Inc. | partner | Counterparty to the License, Development and Commercialization Agreement referenced in the prepayment acknowledgment | 2022-12-06 | View |
| KURA Kura Oncology, Inc. | investor | Purchased 1,370,171 shares of common stock in a registered direct offering for approximately $25.0 million. | 2022-11-03 | View |
| BBIO BridgeBio Pharma, Inc. | partner | Exclusive license agreement for Navire's product candidate BBP-398 | 2022-05-13 | View |
| IPSC Century Therapeutics, Inc. | partner | Collaborator for cancer immunotherapeutics with sublicensing rights in Japan | 2022-01-13 | View |
| BCAB BioAtla, Inc. | partner | Clinical trial collaboration and supply agreement for combination therapies | 2022-01-11 | View |
| IPSC Century Therapeutics, Inc. | partner | Partnered with Century Therapeutics for research, development, and commercialization of cell therapy programs; purchased | 2022-01-10 | View |
| AGEN AGENUS INC | partner | Entered into a License, Development and Commercialization Agreement for the anti-TIGIT bispecific antibody program AGEN1 | 2021-05-18 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-07-30 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-05-08 | Shareholder Vote | View | |
| 2026-04-30 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-02-05 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2026-01-12 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-11-18 | Other Events; Financial Statements and Exhibits | View | |
| 2025-11-10 | Other Events; Financial Statements and Exhibits | View | |
| 2025-11-03 | Other Events; Financial Statements and Exhibits | View | |
| 2025-10-30 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-07-31 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-07-25 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-05-07 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-04-24 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-02-18 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-02-06 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-01-13 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2024-10-31 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2024-07-26 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2024-06-18 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2024-05-09 | Amendments to Articles of Incorporation or Bylaws; Submission of Matters to a Vote of Security Holde | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR